Treatment of Metastatic Breast Carcinoma Refractory to Doxorubicin with Liposomal-Annamycin
Abstract
We studied the toxicity and antitumor activity of Liposomal-Annamycin in patients with metastatic breast carcinoma. Sixteen patients were treated. Toxicity was mild and consisted mostly of bone marrow suppression, particularly granulocytopenia. Non- hematological toxicity was less than what is usually seen with other anthracyclines. No responses were seen.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2001
- Accession Number
- ADA411291
Entities
People
- Aysegul A. Sahin
Organizations
- The University of Texas MD Anderson Cancer Center